Sissma Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 12 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
- Revenue Growth -0.12%
- Profit Growth -11.91%
- Ebitda 179.61%
- Net Worth 2.67%
- Total Assets 3.02%
About Sissma Life Sciences
Sissma Life Sciences Private Limited (SLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 August 2012 and has a history of 12 years and five months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹2.00 M.
Subramanyam Anala, Subbaraju Rudraraju, and Mallikarjunaa Chintalgari serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232TG2012PTC082806
-
Company No.
082806
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Aug 2012
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Sissma Life Sciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subramanyam Anala
|
Director | 30-Aug-2012 | Current |
|
Subbaraju Rudraraju
|
Director | 30-Aug-2012 | Current |
|
Mallikarjunaa Chintalgari
|
Director | 19-Sep-2013 | Current |
Financial Performance of Sissma Life Sciences.
Sissma Life Sciences Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 0.12% decrease. The company also saw a substantial fall in profitability, with a 11.91% decrease in profit. The company's net worth moved up by a moderate rise of 2.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sissma Life Sciences?
In 2019, Sissma Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Massis Medicare Private LimitedSubbaraju Rudraraju is a mutual person
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Dec 2019 | Others | ₹2.00 M | Open |
How Many Employees Work at Sissma Life Sciences?
Unlock and access historical data on people associated with Sissma Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sissma Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sissma Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.